GeneDx Holdings Corp. (NASDAQ:WGS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $150.7143.

Several brokerages have commented on WGS. Zacks Research raised GeneDx from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 25th. Piper Sandler restated an “overweight” rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research report on Wednesday, January 21st. Wall Street Zen cut shares of GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, Wells Fargo & Company raised shares of GeneDx from an “equal weight” rating to an “overweight” rating and set a $155.00 price target for the company in a report on Monday, February 9th.

GeneDx Stock Down 4.8%

WGS stock opened at $68.67 on Wednesday. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of -91.56 and a beta of 2.03. The company has a 50-day moving average of $88.27 and a two-hundred day moving average of $117.93. GeneDx has a 52-week low of $55.17 and a 52-week high of $170.87. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.46 and a quick ratio of 2.34.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The business had revenue of $120.99 million for the quarter, compared to analyst estimates of $120.80 million. As a group, equities research analysts anticipate that GeneDx will post 0.97 EPS for the current year.

Insider Activity at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 17,179 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $76.80, for a total value of $1,319,347.20. Following the completion of the transaction, the chief executive officer owned 58,447 shares of the company’s stock, valued at $4,488,729.60. This represents a 22.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Bryan Dechairo sold 5,961 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $85.70, for a total value of $510,857.70. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 65,875 shares of company stock worth $5,280,990 in the last three months. Corporate insiders own 29.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Jones Financial Companies Lllp lifted its position in GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares during the period. Kestra Advisory Services LLC bought a new stake in GeneDx in the 4th quarter valued at $27,000. Quarry LP raised its stake in shares of GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after buying an additional 209 shares in the last quarter. Ramirez Asset Management Inc. bought a new position in shares of GeneDx during the 4th quarter worth about $33,000. Finally, Greenline Wealth Management LLC bought a new position in shares of GeneDx during the 4th quarter worth about $33,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.